NLRP3 and metabolic dysfunction-associated steatohepatitis: Second, genetic NLRP3 deficiency (Stienstra et al., 2011; Vandanmagsar et al., 2011; Wree et al., 2014a) as well as a specific NLRP3 antagonist (Mridha et al., 2017) halt the progression of NAFLD into NASH.